Mechanistic insights make cancer cachexia a targetable syndrome

A.A.H. reports research support from Merck.

M.H.V. has been an invited speaker for Ideology Health, WebMD, MedNet, Talemhealth, Onclive, Axiom, Clinical Care Options, Targeted Oncology and Mashup Media, and has served on advisory boards for Arcus Biosciences, Aveo, Calithera, Eisai, Exelixis, Genentech, Kura Oncology, Merck, MICU Rx, NiKang Therapeutics and Oncorena.

M.H.V. has received research support from Merck and has been principal investigator on studies funded by AstraZeneca, BMS, Calithera, Exelixis, Genentech, Merck, NiKang Therapeutics, Pfizer, Regeneron and Roche. He has received sponsorship or funding from Exelixis, Eli Lilly, Pfizer and Regeneron, and has held advisory roles with Affimed, Aravive, onQuality, ImmunityBio, AstraZeneca, Mertelsmann Foundation, Genentech, Merck and NiKang Therapeutics.

E.R. reports no competing interests.